CAMBRIDGE, Mass., Aug. 5 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 7,248,936 shares of its common stock at a price of $3.14 per share. After underwriting discounts and commissions and estimated offering expenses, the company expects to receive net proceeds of approximately $21.2 million. All of the shares are being sold by Idenix. The offering is expected to close on August 10, 2009, subject to customary closing conditions.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Idenix, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37(th) Floor, Boston, MA 02110 or by calling toll free, at 1-800-808-7525, Ext. 4814.
SOURCE Idenix Pharmaceuticals, Inc.
CONTACT: Media: Teri Dahlman, +1-617-995-9905, or Investors: Amy Sullivan,
+1-617-995-9838, both of Idenix Pharmaceuticals, Inc.
Web site: http://www.idenix.com/
